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Background: Differential diagnosis among psoriatic arthritis (PsA) and seronegative rheumatoid arthritis (Abneg RA)
can be challenging particularly in the clinical setting of peripheral phenotype and autoantibodies seronegativity.
The aim of the study was to identify synovial tissue (ST) biomarkers differentially expressed in PsA and Abneg RA
and test their predictive value of therapeutic response.
Methods: Thirty-four PsA patients [12 DMARD naive and 22 non-responder to methotrexate (MTX-IR)] with
peripheral joint involvement and 55 Abneg RA (27 DMARD naive and 28 MTX-IR) underwent US-guided ST
biopsy and immunohistochemistry (IHC) for CD68+, CD3+, CD20+, CD21+, CD117+, and CD138+ cells. After
study entry, each DMARD-naive patient started MTX therapy and was followed in an outpatient setting for at
least 6 months to define the achievement of Minimal Disease Activity (PsA) and DAS remission (Abneg RA)
status respectively. Each IR-MTX patient was treated according to EULAR recommendations.
Results: At study entry, IHC analysis revealed that PsA patients had comparable levels of lining and sublining
CD68+ and sublining CD21+, CD20+, and CD3+ cells than Abneg RA, despite the therapeutic regimen.
Moreover, regardless of the therapeutic scheme, PsA patients showed higher IHC score of CD117+ cells (p = 0.
0004 and p = 0.0005 for naive and MTX-IR patients respectively) compared to Abneg RA patients. Conversely,
Abneg RA patients showed higher IHC score of CD138+ cells, irrespective to the therapeutic scheme (p = 0.04
and p = 0.002 for naive and MTX-IR patients respectively). Analyzing the response rate to the therapeutic
scheme, naive PsA patients reaching MDA status at 6 months follow-up, showed, at the study entry, lower
IHC score of CD3+ cells compared to PsA patients not reaching this outcome (p = 0.02); conversely, naive
Abneg RA patients reaching DAS remission status at 6 months follow-up, showed, at the study entry, lower
IHC score of sublining CD68+ cells compared to Abneg RA patients not reaching this outcome (p < 0.001).
Conclusions: CD117+ and CD138+ cells are differentially distributed among PsA and Abneg RA. Histological
analysis of ST may help to solve the clinical overlap between the two diseases and provides prognostic data
about the therapy success.
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Psoriatic arthritis (PsA) is a chronic inflammatory disease
characterized by remarkable heterogeneity of clinical pres-
entation, including peripheral arthritis, axial involvement,
enthesitis, dactylitis, nail dystrophy, uveitis, and osteitis, in
addition to associated comorbidities such as cardiovascu-
lar disease, metabolic syndrome, and mood disorders [1,
2]. Most patients with PsA present with oligoarticular or
polyarticular arthritis and can be differentiated from pa-
tients with rheumatoid arthritis (RA), the most common
inflammatory joint disease, by specific non-articular clin-
ical features being present, as well as the infrequent sero-
positivity for rheumatoid factor (RF) and anti-citrullinated
peptide antibody (ACPA). These clinical features include
an asymmetric distribution of the inflamed joints, the
sacroiliitis or spinal involvement, the typical involvement
of the distal interphalangeal joint (DIP), and the
extra-articular manifestations [1]. However, in clinical
practice, the differential diagnosis among PsA and RA can
be challenging, particularly if the peripheral phenotype is
present and RF and ACPA are negative. In recent years,
there have been a number of advances made in synovial
tissue biopsy techniques in patients with inflammatory
joint diseases [3]. However, despite many research groups
have focused on the analysis of possible differential bio-
markers among PsA and RA, no studies have been per-
formed considering a direct comparison between PsA
with a RF/ACPA seronegative (Abneg) RA cohort [4, 5].
Based on that, the aims of the study were (i) to assess
whether the histological characteristics of synovial tissue
of PsA patients with peripheral arthritis phenotype com-
pared to seronegative RA patients could differ in differ-
ent disease phases and (ii) to evaluate possible predictive
synovial biomarkers associated with treatment response
in PsA and seronegative RA patients at disease onset
and after c-DMARD failure.
Patients and methods
Patient enrollment
Eighty-nine patients were enrolled in the study [34
oligo-polyarticular PsA patients (12 naïve and 22 inad-
equately responder to methotrexate (MTX-IR) respectively)
and 55 RA patients (27 naïve and 28 MTX-IR respectively)]
fulfilling the classification criteria for PsA or RA [6, 7]. At
baseline, demographical, clinical, and inflammatory parame-
ters were collected for each patient. All RA patients were
confirmed as being seronegative (Abneg) for IgA- and
IgM-RF (Orgentec Diagnostika, Bouty, UK) and ACPA
(Axis Shield Diagnostics, Bouty, UK) using commercial
ELISA at study entry. Each naïve PsA and Abneg RA patient
was then treated with methotrexate (up to 20mg/week) and
followed every 3months for at least 6months to assess the
rate of achievement of Minimal Disease Activity (MDA) or
DAS remission for PsA and Abneg RA patients respectively[8, 9]. MTX-IR PsA and Abneg RA patients were treated ac-
cording to the current recommendations [10, 11]. The study
protocol was approved by the local Ethical Committee, and
all subjects provided signed informed consent.
Immunohistochemistry for CD68, CD21, CD3, CD20,
CD138, CD117, and CD31 on synovial tissue
At study entry, each PsA and Abneg RA patient underwent
ultrasound-guided synovial tissue biopsy of the knee. Joint
inflammatory activity was tested for each patient using
power Doppler as previously described [12]. Each tissue
was tested through immunohistochemistry for the pres-
ence of CD68 (macrophages), CD21 (follicular dendritic
cells), CD3 (T lymphocytes), CD20 (B lymphocytes), and
CD31 (endothelial cells) staining following the already
published protocol [12]. Other tissue sections were stained
for plasma cell and mast cell detection, using CD138
mouse antihuman monoclonal antibody (clone MI15) or
CD117 mouse antihuman monoclonal antibody (clone
EP10) (all from Leica Biosystem, Newcastle, UK) by
immunostainer BOND MAX III (Leica). Slides were ex-
amined by two independent evaluators using a light
microscope (Leica DM 2000), and all tissues were evalu-
ated using a numerical score based on the number of
CD68+, CD21+, CD3+, CD20+, CD117+, and CD138+ cells
(two different fields in each section), with a score of 0 in-
dicating no positive cells, 1 indicating < 10% positive cells,
2 indicating 10–50% positive cells, and 3 indicating > 50%
positive cells. CD31+ vessel count was done as mean of
the values from three different fields in each section [12].
The inter-rater agreement coefficient was assessed for
each single IHC marker (see Additional file 2: Table S1).
Statistical analysis
Statistical analysis was performed using SPSS V. 20.0
(SPSS. Chicago, IL, USA) and Prism software (GraphPad,
San Diego, CA, USA). Categorical and quantitative vari-
ables were described as frequencies, percentage, and
mean ± SD. Data on demographic and clinical features
were compared between patients by the non-parametric
Mann-Whitney U test or χ2 test, as appropriate. Spear-
man’s rank correlation test was used for correlation in all
analyses. ROC analysis was performed to identify the best
cut-off value for IHC scores associated with the highest
rate of MDA or DAS remission achievement in PsA and
Abneg RA patients respectively. A value of p ≤ 0.05 was
considered statistically significant.
Results
Demographic and clinical characteristics of the enrolled
study cohorts
Demographic and clinical characteristics of PsA and
Abneg RA cohorts (naïve and MTX-IR respectively) en-
rolled in the study are summarized in Table 1.
Table 1 Demographical, clinical, and immunological characteristics of the study cohorts
PsA (n = 34) p Abneg RA (n = 55) p1 p2 p3
Naive (n = 12) MTX-IR (n = 22) Naive (n = 27) MTX-IR (n = 28)
Age, years (mean ± SD) 54.75 ± 17.18 60.18 ± 9.81 0.47 52.41 ± 17.70 58.36 ± 16.58 0.16 0.68 0.77
Female, n (%) 4 (33.3) 14 (63.6) 0.10 23 (85.2) 23 (82.1) 0.76 0.001 0.14
Disease duration, years (mean ± SD) 0.80 ± 0.24 5.83 ± 3.68 < 0.001 0.84 ± 0.95 5.68 ± 5.28 0.002 0.44 0.49
DAS44 (mean ± SD) 3.00 ± 0.42 3.34 ± 0.91 0.34 3.37 ± 1.05 3.22 ± 0.79 0.71 0.52 0.81
DAPSA (mean ± SD) 22.55 ± 8.38 28.04 ± 10.14 0.10 – – – – –
SJC (mean ± SD) 4.00 ± 2.67 6.43 ± 5.69 0.35 8.22 ± 7.95 7.15 ± 5.53 0.93 0.18 0.54
TJC (mean ± SD) 5.00 ± 3.16 7.00 ± 6.13 0.66 8.22 ± 7.86 8.44 ± 5.46 0.33 0.51 0.24
ESR, mm/1st hour (mean ± SD) 29.60 ± 36.94 29.10 ± 19.59 0.44 44.00 ± 25.40 37.04 ± 27.25 0.19 0.03 0.44
CRP, mg/l (mean ± SD) 16.70 ± 29.16 18.11 ± 23.41 0.70 16.99 ± 19.43 16.77 ± 24.23 0.77 0.72 1.00
Ab positivity, n (%) 0 (0.0) 0 (0.0) 1.00 0 (0.0) 0 (0.0) 1.00 1.00 1.00
Data presented in italics have p < 0.05
PsA psoriatic arthritis, RA rheumatoid arthritis, Ab autoantibody, DAS Disease Activity Score, DAPSA Disease Activity in PSoriatic Arthritis, SJC swollen joint count,
TJC tender joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SD standard deviation, MTX-IR methotrexate inadequately responder, p naive
PsA vs MTX-IR PsA, p1 naive Abneg RA vs MTX-IR Abneg RA, p2 naive PsA vs naive Abneg RA, p3 MTX-IR PsA vs MTX-IR Abneg RA
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significant differences according to age and gender (p >
0.05). PsA and Abneg RA patients naïve to treatment
showed significant shorter disease duration (0.80 ± 0.24
years for naive PsA and 0.84 ± 0.95 Abneg RA patients
respectively) compared to MTX-IR PsA and Abneg RA
patients (5.83 ± 3.68 years for MTX-IR PsA, p < 0.001;
5.68 ± 5.28 for MTX-IR Abneg RA patients, p = 0.002 re-
spectively). Considering the clinical parameters, there
were no significant differences comparing PsA and Abneg
RA patients based on swollen and tender joint counts or
Disease Activity Scores in naïve and in MTX-IR sub-
groups (Table 1). However, considering inflammatory
markers, ESR plasma levels were significantly higher in
naïve Abneg RA patients (44.00 ± 25.40 mm/first hour)
than MTX-IR Abneg RA patients (29.60 ± 36.94 mm/first
hour; p = 0.03), whereas no differences were found for
CRP plasma levels comparing naïve and MTX-IR PsA
subgroups (Table 1).
PsA and Abneg RA show similar histological features in
terms of synovial resident CD68+, CD21+, and CD3+ cells
and microanatomical organization
Each enrolled patient underwent US-guided ST biopsy,
and IHC for CD68+, CD21+, CD20+, and CD3+ was per-
formed. PsA patients showed similar IHC CD68+ cell
score in the lining (1.95 ± 0.90) and sublining (1.81 ± 0.95)
compared to Abneg RA patients (1.96 ± 0.75 for lining
CD68+ cells, p = 0.94; 1.43 ± 0.76 for sublining CD68+
cells, p = 0.11 respectively) regardless of the treatment
scheme (Fig. 1a–d). Furthermore, IHC analysis revealed
that PsA and Abneg RA patients had comparable levels of
CD21+ cells (0.72 ± 0.79 vs 0.60 ± 0.95; p = 0.18 respect-
ively) regardless of the treatment scheme (Fig. 1a–d).Stratifying the study cohorts according to the treat-
ment scheme, naïve PsA showed similar IHC scores for
lining (2.00 ± 0.85) and sublining CD68+ cells (1.71 ±
0.96) compared to naïve Abneg RA patients (1.96 ± 0.79
for lining CD68+ cells, p = 1.00; 1.44 ± 0.80 for sublining
CD68+ cells, p = 0.39 respectively). Moreover, naïve PsA
showed similar IHC scores for CD21+ cells (0.75 ± 0.94)
compared to naïve Abneg RA patients (0.52 ± 0.91; p =
0.43) (Fig. 1g), showing a direct correlation between ESR
plasma levels and lining CD68+ cells IHC score (r = 0.66;
p = 0.04). Similarly, MTX-IR PsA patients showed com-
parable IHC scores for lining (1.92 ± 0.95) and sublining
CD68+ cells (1.86 ± 0.96) than MTX-IR Abneg RA pa-
tients (2.00 ± 0.72 for lining CD68+ cells, p = 0.79; 1.46 ±
0.78 for sublining CD68+ cells, p = 0.25) (Fig. 1e–h). Fi-
nally, MTX-IR PsA showed similar IHC scores for
CD21+ cells (0.71 ± 0.73) compared to MTX-IR Abneg
RA patients (0.68 ± 1.00; p = 0.91) (Fig. 1g).
Analyzing the microanatomical organization of the
synovial tissue infiltrates, 15 (44.1%) PsA patients com-
pared to 24 (43.6%, p = 0.51) Abneg RA patients showed
follicular synovitis regardless of the treatment regimen.
Moreover, there was no difference in the rate of follicu-
lar synovitis stratifying patients according to the thera-
peutic regimen (41.7% of naïve PsA patients with
follicular synovitis compared to 45.5% of MTX-IR PsA
patients with similar synovitis pattern, p = 0.79; 44.4% of
naïve Abneg RA patients with follicular synovitis com-
pared to 42.8% of MTX-IR Abneg RA patients with simi-
lar synovitis pattern, p = 0.51).
CD20 IHC revealed that PsA and Abneg RA patients
had similar levels of CD20+ cells (1.08 ± 0.73 in PsA vs
1.44 ± 0.89 in Abneg RA, p = 0.07) (Fig. 2a–d) and after
stratification based on the treatment regimen, PsA
Fig. 1 a–g IHC staining for CD68/CD21 on ST of patients with naïve or MTX-IR PsA and Abneg RA patients. Example photos of CD68 (RED)/CD21(DAB) staining
of ST biopsies from patients with naïve (a) or MTX-IR (b) PsA patients and with naïve (c) or MTX-IR (d) Abneg RA (magnification × 20 and magnification × 40 in
the corresponding inset). Black arrows indicate CD68+ cells (red), and black arrow head indicates CD21+ cells (brown) in the corresponding inset. e Lining IHC
score for CD68+ cells in PsA and Abneg RA patients divided by treatment regimen. f Sublining IHC score for CD68+ cells in PsA and Abneg RA patients divided
by treatment regimen. g IHC score for CD21+ cells in PsA and Abneg RA patients divided by treatment regimen. IHC immunohistochemistry, PsA psoriatic
arthritis, RA rheumatoid arthritis, Ab autoantibody, MTX-IR methotrexate inadequately responder, CD cluster designation
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Abneg RA (1.00 ± 0.85 in naive PsA vs 1.44 ± 0.92 in
naive Abneg RA, p = 0.16; 1.14 ± 0.67 in MTX-IR PsA vs
1.45 ± 0.87 MTX-IR Abneg RA, p = 0.18) (Fig. 2e).
Analyzing synovial CD3+ cell distribution, IHC showed
that PsA and Abneg RA patients had similar levels of
synovial CD3+ cells (1.71 ± 0.86 in PsA and 1.54 ± 0.86
in Abneg RA; p = 0.45 respectively) (Fig. 2a–d). Moreover,
PsA and Abneg RA patients did not differ in terms ofsynovial CD3+ cells stratifying patients based on the
treatment scheme (1.45 ± 0.83 in naive PsA vs 1.57 ±
0.88 in naïve Abneg RA, p = 0.70; 1.84 ± 0.86 in MTX-IR
PsA vs 1.52 ± 0.87 MTX-IR Abneg RA, p = 0.19) (Fig. 2f ).
Synovial CD117+ and CD138+ cells are differentially
distributed in PsA and Abneg RA patients
CD117 IHC showed that PsA patients are characterized
by higher IHC scores for CD117+ cells (1.25 ± 0.61)
Fig. 2 a–f IHC staining for CD3/CD20 on ST of patients with naïve or MTX-IR PsA and Abneg RA patients. Example photos of CD3 (RED)/CD20
(DAB) staining of ST biopsies from patients with naïve (a) or MTX-IR (b) PsA patients and with naïve (c) or MTX-IR (d) Abneg RA patients
(magnification × 20 and magnification × 40 in the corresponding inset). Thin black arrows indicate CD3+ cells (red), and black arrow heads
indicate CD20+ cells (brown) in the corresponding inset. e IHC scores for CD20+ cells in PsA and Abneg RA patients divided by treatment regimen.
f IHC scores for CD3+ cells in PsA and Abneg RA patients divided by treatment regimen. IHC immunohistochemistry, PsA psoriatic arthritis, RA
rheumatoid arthritis, Ab autoantibody, MTX-IR methotrexate inadequately responder, CD cluster designation
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regardless of the treatment scheme (Fig. 3a–d). Interest-
ingly, stratifying the study cohorts according to the
treatment scheme, naïve PsA patients showed higher
CD117+ cell IHC scores (1.29 ± 0.65) compared to naïve
Abneg RA patients (0.59 ± 0.44; p = 0.0004). Similarly,
MTX-IR PsA patients showed higher CD117+ IHC score
(1.23 ± 0.61) compared to MTX-IR Abneg RA patients
(0.64 ± 0.48, p = 0.001) (Fig. 3e).
Conversely, analyzing the distribution of CD138+ cells
within the synovial tissue, Abneg RA patients showed higher
IHC scores for CD138+ cells (1.58 ± 1.09) compared to PsA
patients (0.72 ± 0.71; p < 0.001) independently of the treat-
ment scheme (Fig. 3f–i). Considering the different study
population subgroups, naive Abneg RA patients werecharacterized by higher CD138+ cell IHC score (1.65 ±
1.00) compared to naive PsA patients (0.96 ± 0.84; p = 0.04).
Similarly, MTX-IR Abneg RA patients had higher CD138+
cell IHC score (1.51 ± 1.19) compared to MTX-IR PsA pa-
tients (0.59 ± 0.61, p = 0.002) (Fig. 3j). As shown in Fig. 3k,
the combination of low IHC score for CD117+ (IHC score
= 1) and high IHC score for CD138+ cells (IHC score = 3)
significantly differentiates PsA than Abneg RA synovitis [OR
(95% CI), 34.04 (1.535–2.398); p = 0.0002].
Synovial CD31+ vessel count is associated with the
disease phase in PsA and Abneg RA patients
To assess the microvasculature at the synovial tissue
level, each tissue was tested for the presence of CD31+
blood vessels. As shown in Fig. 4a–e, naïve PsA patients
Fig. 3 a–k IHC staining for CD117 and CD138 on ST of patients with naïve or MTX-IR PsA and Abneg RA patients. Example photos of CD117 (RED) staining of
ST biopsies from patients with naïve (a) or MTX-IR (b) PsA and with naïve (c) or MTX-IR (d) Abneg RA (magnification × 20 and magnification × 40 in the
corresponding inset). Thin black arrows indicate CD117+ cells (red) in the corresponding inset. e IHC scores for CD117+ cells in PsA and Abneg RA patients
divided by treatment regimen; *p=0.0004, naïve PsA vs naïve Abneg RA patients; *p =0.0005, MTX-IR PsA vs MTX-IR Abneg RA patients. Example photos of
CD138 (DAB) staining of ST biopsies from patients with naïve (f) or MTX-IR (g) PsA and with naïve (h) or MTX-IR (i) Abneg RA (magnification × 20 and
magnification × 40 in the corresponding inset). Thin black arrows indicate CD138+ cells (brown) in the corresponding inset. j IHC scores for CD138+ cells in PsA
and Abneg RA patients divided by treatment regimen; *p =0.04, naive PsA vs naive AbnegRA patients; *p=0.002, MTX-IR PsA vs MTX-IR Abneg RA patients.
k Rate of distribution of CD117/CD138 IHC combination differentially distributed among PsA and Abneg RA patients. IHC immunohistochemistry, PsA psoriatic
arthritis, RA rheumatoid arthritis, Ab autoantibody, MTX-IR methotrexate inadequately responder, CD cluster designation
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Fig. 4 a–e IHC staining for CD31 on ST of patients with naïve or
MTX-IR PsA and Abneg RA patients. Example photos of CD31 (DAB)
staining of ST biopsies from patients with naïve (a) or MTX-IR (b) PsA
and with naïve (c) or MTX-IR (d) Abneg RA (magnification × 20 and
magnification × 40 in the corresponding inset). Thin black arrows
indicate CD31+ vessels (brown) in the corresponding inset. e Synovial
CD31+ vessel count in PsA and Abneg RA patients divided by treatment
regimen; *p= 0.01, naïve vs MTX-IR PsA patients; *p< 0.001, naïve vs
MTX-IR Abneg RA patients. IHC immunohistochemistry, PsA psoriatic
arthritis, RA rheumatoid arthritis, Ab autoantibody, MTX-IR methotrexate
inadequately responder, CD cluster designation
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± 11.02) compared to MTX-IR PsA patients (23.65 ±
11.67; p = 0.01). Similarly, naïve Abneg RA patients
showed a higher number of synovial CD31+ vessels
(35.43 ± 7.23) than MTX-IR Abneg RA patients (22.14 ±
5.32; p < 0.001). No significant differences in terms ofCD31+ vessel count were found comparing PsA and
Abneg RA patients stratified based on the same treat-
ment category (Fig. 4e).
Baseline synovial CD3+ and CD68+ cell IHC scores are
associated with Minimal Disease Activity and remission
achievement in PsA and Abneg RA patients naïve to
treatment respectively
After study enrollment, each naïve patient started metho-
trexate treatment and was followed for at least 6months on
outpatient setting and treatment response rate was recorded
at each clinical assessment (MDA for PsA and DAS remis-
sion for Abneg RA patients respectively). After 6months
follow-up from methotrexate beginning, 6 (50.0%) PsA pa-
tients achieved MDA, while 11 (40.7%) Abneg RA patients
achieved DAS remission. As shown in Table 2, naïve PsA
patients who reached the MDA status at 6months
follow-up had lower CD3+ cell IHC score (0.91 ± 0.33) be-
fore methotrexate beginning, compared to naïve PsA pa-
tients who did not achieve the clinical endpoint at 6months
(1.99 ± 0.84; p= 0.02). Conversely, naïve Abneg RA patients
who reached the DAS remission status at 6months
follow-up had lower sublining CD68+ cell IHC score (0.92 ±
0.58) before methotrexate beginning, compared to naïve
Abneg RA patients who did not achieved the clinical end-
point at 6months (2.13 ± 0.55; p < 0.001) (Table 2). To de-
fine the best cut-off value for CD3+ cell scores and CD68+
cell sublining scores in naive PsA and Abneg RA respectively,
ROC analysis was performed for each parameter (Add-
itional file 1: Figure S1a-b). In particular, naive PsA patients
who reached a MDA status after 6months follow-up had
more likely baseline CD3+ cell scores< 1.25 (83.3%) than
naive PsA patients who did not reach MDA status (16.7%, p
= 0.02). Moreover, naive Abneg RA patients who reached
DAS remission after 6months follow-up had more likely
baseline CD68+ cell sublining scores < 2.25 (65.0%) than
naive Abneg RA patients who did not reach DAS remission
(0.0%, p= 0.03). In relation to MTX-IR patients, there was
no significant difference in MDA and DAS remission status
achievement in PsA and Abneg RA patients respectively,
even stratifying patients based on the therapeutic strategy
after MTX failure (c-DMARD combination or addition of
b-DMARDs) (40.0% MTX-IR PsA patients achieved MDA
after c-DMARD combination vs 64.7% MTX-IR PsA pa-
tients achieved MDA after b-DMARD addition, p= 0.32;
44.4% MTX-IR Abneg RA patients achieved MDA after
c-DMARD combination vs 50.0% MTX-IR Abneg RA pa-
tients achieved MDA after b-DMARD addition, p= 0.78).
Discussion
As in RA, synovial membrane inflammation plays a key
pathogenetic role in PsA and many studies have focused
on this topic in the last decades, especially looking for
differential synovial tissue biomarkers between different
Table 2 IHC features of PsA and Abneg RA cohorts based on the achievement of MDA and DAS remission after 6 months follow-up
PsA cohort
Naive (N = 12) p MTX-IR (N = 22) p1
MDA (N = 6) No MDA (N = 6) MDA (N = 9) No MDA (N = 13)
Follicular synovitis, n (%) 3 (50.0) 3 (50.0) 1.00 3 (33.3) 7 (53.8) 0.34
CD68 (L) (mean ± SD) 1.58 ± 0.80 2.42 ± 0.73 0.09 1.86 ± 0.90 2.0 ± 1.07 0.77
CD68 (SL) (mean ± SD) 1.25 ± 1.08 2.16 ± 0.61 0.13 1.77 ± 0.93 2.0 ± 1.07 0.54
CD21 (mean ± SD) 0.58 ± 0.92 0.92 ± 1.02 0.59 0.96 ± 0.80 0.33 ± 0.43 0.06
CD20 (mean ± SD) 0.83 ± 0.82 1.17 ± 0.93 0.56 1.19 ± 0.83 1.06 ± 0.40 0.64
CD3 (mean ± SD) 0.91 ± 0.33 1.99 ± 0.84 0.02 1.65 ± 0.77 2.11 ± 0.96 0.29
CD117 (mean ± SD) 1.16 ± 0.82 1.42 ± 0.49 0.62 1.12 ± 0.62 1.39 ± 0.61 0.32
CD138 (mean ± SD) 0.67 ± 0.75 1.25 ± 0.88 0.25 0.58 ± 0.64 0.61 ± 0.60 0.84
CD31+ vessels (mean ± SD) 32.50 ± 13.41 40.75 ± 6.84 0.39 22.81 ± 11.31 25.21 ± 13.06 0.58
Abneg RA cohort
Naive (N = 27) p2 MTX-IR (N = 28) p3
REM (N = 11) No REM (N = 16) REM (N = 11) No REM (N = 17)
Follicular synovitis, n (%) 6 (46.2) 6 (42.6) 0.86 3 (27.3) 7 (41.2) 0.45
CD68 (L) (mean ± SD) 1.86 ± 0.82 2.23 ± 0.68 0.27 2.10 ± 0.51 1.97 ± 0.83 0.82
CD68 (SL) (mean ± SD) 0.92 ± 0.58 2.13 ± 0.55 < 0.001 1.35 ± 0.78 1.46 ± 0.76 0.66
CD21 (mean ± SD) 0.39 ± 0.74 0.65 ± 1.08 0.79 0.54 ± 0.79 0.77 ± 1.13 0.78
CD20 (mean ± SD) 1.64 ± 1.02 1.23 ± 0.78 0.26 1.46 ± 0.99 1.44 ± 0.83 0.85
CD3 (mean ± SD) 1.57 ± 0.95 1.57 ± 0.83 0.98 1.59 ± 0.89 1.47 ± 0.87 0.49
CD117 (mean ± SD) 0.57 ± 0.43 0.62 ± 0.46 0.79 0.77 ± 0.56 0.56 ± 0.43 0.28
CD138 (mean ± SD) 1.54 ± 0.99 1.77 ± 1.05 0.55 1.36 ± 1.07 1.62 ± 1.28 0.47
CD31+ vessels (mean ± SD) 35.64 ± 7.69 34.64 ± 6.89 0.54 22.35 ± 5.28 21.88 ± 5.78 0.52
Data presented in italics have p < 0.05
PsA psoriatic arthritis, Ab autoantibody, RA rheumatoid arthritis, MDA Minimal Disease Activity, REM remission, DAS Disease Activity Score, p naive PsA reaching
MDA vs naive PsA not achieving MDA, p1 MTX-IR PsA reaching MDA vs MTX-IR PsA not achieving MDA, p2 naive ABneg RA reaching DAS remission vs naive ABneg
RA not achieving DAS remission, p3 MTX-IR ABneg RA reaching DAS remission vs MTX-IR ABneg RA not achieving DAS remission, MTX-IR methotrexate
inadequately responder
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cently, the new advances in collecting synovial tissue
through minimally invasive techniques have provided
insight into the pathogenetic mechanisms of such joint
diseases and facilitate differential diagnosis, stratification
prognosis, and identification of treatment effects and
new therapeutic targets [13].
In our study, we investigated, for the first time, the syn-
ovial histological features of a selected cohort of PsA pa-
tients, with peripheral joint involvement, compared to
ACPA/RF seronegative RA cohort stratified based on the
disease phase (disease onset and after DMARD insuffi-
cient response respectively) finding differential histological
features of synovial tissue inflammation composition and
biomarkers of therapeutic response.
Both RA and PsA are systemic autoimmune diseases
characterized by chronic inflammation of the joint which
leads to the destruction of the cartilage and bone [14, 15].
In particular, the clinical presentation of PsA is heteroge-
neous, variably involving the synovium of peripheraljoints, spine, and/or entheses [6]. Moreover, PsA patients
may develop articular structural damage both in terms of
erosions and new bone formation and may also develop
systemic complications including the development of
metabolic syndrome and increased cardiovascular risk
with concomitant reduced life expectancy [16, 17]. The
synovium in PsA represents a primary target of disease
pathogenesis, together with the skin and entheses, with a
distinct gene signature compared to healthy and other
joint diseases [18]. Thus, it is an intriguing and plausible
site in exploring important mechanisms of the disease.
Multiple studies have characterized the histological
features of synovitis in PsA compared with RA, proving
that there are some substantial histological differences;
notably, the PsA synovitis was shown to be characterized
by less pronounced lining layer hyperplasia and fewer
monocytes/macrophages than are seen in RA [19–21].
Given that it has already been clearly shown that oli-
goarticular and polyarticular PsA presents comparable
histopathological characteristics [4], in PsA, there is a
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vascular pattern, characterized by immature, tortuous,
and branched vessels, compared with the straight blood
vessels more likely observed in RA [22].
Despite these advances, currently, there are no differ-
ential synovial tissue biomarkers between PsA and RA
especially if the latter is diagnosed in a clinical setting of
negativity for ACPA and RF antibodies. This particular
setting may create difficulties in terms of differential
diagnosis and prognosis in the earliest undifferentiated
phase of the disease. To address this issue, we have pre-
viously demonstrated that synovial tissue analysis in
terms of histological, ultrasound, and epigenetic signa-
ture may support the clinician in the identification of pa-
tients with ACPA/RF seronegative undifferentiated
arthritis with high likelihood chance of clinical differen-
tiation towards definite arthritis (PsA or RA) [23]. In
particular, synovial tissue enriched with CD68+ and
CD3+ cells and high CD31+ vessels characterized ACPA/
RF seronegative undifferentiated arthritis patients evolv-
ing into Abneg RA or PsA [23].
Comparing PsA and Abneg RA, histological analysis of
synovial tissue composition revealed similarities in lining
and sublining CD68+ and sublining CD21+, CD20+, and
CD3+ cell distribution. Previously, controversial data were
reported about CD3+ cell distribution among PsA and
RA. However, no study has been conducted selecting
Abneg RA patients only as the comparison group and mul-
tiple methods of synovial tissue collection were used
(arthroscopic or needle biopsies vs tissue obtained during
joint replacement surgery) [24–26]. Other inflammatory
cells such as mast cells and plasma cells take part in the
tissue inflammatory infiltrate in PsA and RA [27, 28]. In
particular, CD117+ cells have been previously shown more
likely in synovial tissue of SpA, including PsA, expressing
significantly more interleukin-17 than in RA synovitis re-
gardless of TNF inhibition [27]. In our cohort, synovial tis-
sue of PsA patients was found to be enriched in CD117+
cells in the sublining area compared to Abneg RA irre-
spective of the disease phase. Interestingly, CD117+ distri-
bution was found more likely in the context of tissue
lymphoid aggregates. Conversely, synovial tissue of Abneg
RA patients was found to be enriched in CD138+ cells
compared to PsA synovial tissue, underlining the crucial
role of B lymphocytes in RA pathogenesis and suggesting
the need to investigate additional autoantibody specific-
ities despite ACPA/RF negativity in such patient category.
Moreover, the detection of lympho-neogenesis is a fre-
quent feature of PsA synovitis with the expression of per-
ipheral lymph node addressin-positive high endothelial
venules and CXCL13/CCL21 expression demonstrating
that the microanatomical bases for germinal center forma-
tion are present in PsA synovial tissue [29]. In this con-
text, the concept of the autoimmune nature of PsAdisease is strengthened by the recent detection of auto-
antibodies against modified antigens in the peripheral
blood and synovial tissue of early naive to treatment PsA
patients [30].
Increased vascularity has been reported in both psoriatic
skin lesions and synovial tissue in PsA. In the dermis of
the psoriatic skin, an abundance of dilated and tortuous
blood vessels is present [31]. Multiple authors have re-
ported that PsA synovium is characterized by an increase
in macroscopically tortuous blood vessels, and this is more
pronounced in, but not exclusive to, PsA than it is in RA
synovium [20, 32]. In our study cohort, CD31 IHC re-
vealed that the mean number of synovial CD31+ vessels
does not differ among PsA and Abneg RA, suggesting that
the microscopical level does not mirror the macroscopical
view of synovial vasculature in PsA compared to RA once
disease phase stratification is done.
The development of novel biomarkers of therapeutic
response prediction is urgently needed for PsA and RA
management. Previous studies have investigated the ef-
fect of histological markers of synovitis in PsA and RA
mirroring the therapeutic response to conventional and
biological DMARDs respectively [33–35]. In particular,
Pontifex et al. proposed IHC score for sublining CD3+
cells as a useful biomarker of treatment response in PsA,
enrolling a PsA cohort treated with TNF inhibitor [36]
without providing clear cut-off value to be used at treat-
ment initiation in naive PsA patients. In our study co-
horts, we found that naive to treatment PsA with high
likelihood of MDA achievement after DMARD treat-
ment was more likely characterized, at baseline, by IHC
score for CD3+ cells < 1.25 compared to PsA patients
not achieving this clinical outcome. Conversely, valid-
ation studies in RA patients, regardless of the auto-
immune profile, found that variation in IHC score of
sublining CD68+ cells is a valuable synovial biomarker
mirroring the treatment response to conventional and
biological DMARDs (rituximab and TNF inhibitor)
[37–39]. Interestingly, in our study, we confirmed these
findings in a well-selected naive to treatment Abneg RA
patient cohort in which Abneg RA patients with high
likelihood chance of DAS remission achievement after
DMARD treatment were more likely characterized, at
baseline, by IHC score for sublining CD68+ cells < 2.5
compared to Abneg RA patients not achieving DAS re-
mission after DMARD treatment.
Conclusions
In conclusion, our comparative study assessing the
histological features of synovial tissues obtained from
naive to treatment and MTX-IR PsA and Abneg RA pa-
tients revealed that PsA synovitis is characterized by be-
ing mast cell (CD117+) rich but plasma cell (CD138+)
poor whereas Abneg RA synovitis by the reverse findings,
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poor. These different histopathologic biomarkers may
help to solve the diagnostic overlapping issue in the set-
ting of ACPA/RF negativity at the disease onset. More-
over, baseline IHC scores of CD3+ and sublining CD68+
arose as useful biomarkers of treatment response to
first-line DMARDs in PsA and Abneg RA respectively,
suggesting the need to include both parameters in more
extensive future synovial tissue biopsy-driven clinical tri-
als for these inflammatory joint conditions.
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